search
Back to results

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (RELATIVITY-047)

Primary Purpose

Melanoma

Status
Active
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Relatlimab
Nivolumab
Sponsored by
Bristol-Myers Squibb
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Melanoma focused on measuring Cancer, Advanced Cancer

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Participants must have histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the AJCC staging system
  • Participants must not have had prior systemic anticancer therapy for unresectable or metastatic melanoma
  • Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses

Exclusion Criteria:

  • Participants must not have active brain metastases or leptomeningeal metastases
  • Participants must not have uveal melanoma
  • Participants must not have an active, known, or suspected autoimmune disease

Other protocol defined inclusion/exclusion criteria could apply

Sites / Locations

  • Local Institution - 0010
  • Local Institution - 0020
  • Coastal Integrative Cancer Care
  • Local Institution - 0116
  • Local Institution - 0012
  • Local Institution - 0013
  • Local Institution - 0117
  • Local Institution - 0007
  • Local Institution - 0038
  • Local Institution - 0016
  • Local Institution - 0114
  • Local Institution - 0077
  • Local Institution - 0120
  • Local Institution - 0014
  • Local Institution - 0134
  • Local Institution - 0015
  • Local Institution - 0009
  • Local Institution - 0011
  • Local Institution - 0018
  • Local Institution - 0019
  • Local Institution - 0076
  • Local Institution - 0008
  • Local Institution - 0135
  • Local Institution - 0002
  • Local Institution - 0004
  • Local Institution - 0005
  • Local Institution - 0003
  • Local Institution - 0042
  • Local Institution - 0043
  • Local Institution - 0041
  • Local Institution - 0045
  • Local Institution - 0133
  • Local Institution - 0044
  • Local Institution - 0036
  • Local Institution - 0037
  • Local Institution - 0035
  • Local Institution - 0047
  • Local Institution - 0049
  • Local Institution - 0048
  • Local Institution - 0058
  • Local Institution - 0057
  • Local Institution - 0061
  • Local Institution - 0073
  • Local Institution - 0063
  • Local Institution - 0059
  • Local Institution - 0060
  • Local Institution - 0062
  • Local Institution - 0124
  • Local Institution - 0068
  • Local Institution - 0128
  • Local Institution - 0123
  • Local Institution - 0075
  • Local Institution - 0001
  • Local Institution - 0096
  • Local Institution - 0095
  • Local Institution - 0105
  • Local Institution - 0103
  • Local Institution - 0104
  • Local Institution - 0100
  • Local Institution - 0102
  • Local Institution - 0119
  • Local Institution - 0101
  • Local Institution - 0084
  • Local Institution - 0079
  • Local Institution - 0080
  • Local Institution - 0085
  • Local Institution - 0081
  • Local Institution - 0083
  • Local Institution - 0078
  • Local Institution - 0082
  • Local Institution - 0131
  • Local Institution - 0071
  • Local Institution - 0032
  • Local Institution - 0030
  • Local Institution - 0027
  • Local Institution - 0033
  • Local Institution - 0132
  • Local Institution - 0074
  • Local Institution - 0029
  • Local Institution - 0028
  • Local Institution - 0072
  • Local Institution - 0034
  • Local Institution - 0031
  • Local Institution - 0064
  • Local Institution - 0065
  • Local Institution - 0086
  • Local Institution - 0088
  • Local Institution - 0087
  • Local Institution - 0111
  • ASST Papa Giovanni XXIII - Azienda Ospedaliera Papa Giovanni XXIII
  • Local Institution - 0108
  • Istituto Nazionale Tumori Fondazione Pascale
  • Istituto Oncologico Veneto IOV
  • AOUS - Policlinico S.Maria Alle Scotte
  • Local Institution - 0094
  • Local Institution - 0091
  • Local Institution - 0093
  • Local Institution - 0092
  • Local Institution - 0129
  • Local Institution - 0090
  • Local Institution - 0125
  • Local Institution - 0089
  • Local Institution - 0121
  • Local Institution - 0040
  • Local Institution - 0039
  • Local Institution - 0070
  • Local Institution - 0066
  • Local Institution - 0067
  • Local Institution - 0069
  • Local Institution - 0113
  • Local Institution - 0127
  • Local Institution - 0112
  • Local Institution - 0023
  • Local Institution - 0024
  • Local Institution - 0025
  • Local Institution - 0026
  • Local Institution - 0021
  • Local Institution - 0022
  • Local Institution - 0098
  • Local Institution - 0099
  • Local Institution - 0118
  • Local Institution - 0122
  • Local Institution - 0052
  • Local Institution - 0054
  • Local Institution - 0056
  • Local Institution - 0051
  • Local Institution - 0126

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Arm A: Relatlimab + Nivolumab

Arm B: Nivolumab

Arm Description

Combination

Monotherapy

Outcomes

Primary Outcome Measures

Progression Free Survival (PFS)
Progression Free Survival (PFS) is defined as the time between the date of randomization and the date of first documented tumor progression, assessed by a blinded independent central review (BICR) (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. Subjects who die without a reported progression will be considered to have progressed on the date of their death.

Secondary Outcome Measures

Overall Survival (OS)
Overall Survival (OS) is defined as the time between the date of randomization and the date of death due to any cause. For subjects that are alive, their survival time will be censored at the date of last contact ("last known alive date").
Overall Response Rate (ORR)
Objective response rate (ORR) is defined as the number of randomized subjects who achieve a best response of complete response (CR) or partial response (PR) based on BICR assessments (using RECIST v1.1 criteria).

Full Information

First Posted
March 14, 2018
Last Updated
September 15, 2023
Sponsor
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT03470922
Brief Title
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
Acronym
RELATIVITY-047
Official Title
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 11, 2018 (Actual)
Primary Completion Date
January 25, 2021 (Actual)
Study Completion Date
December 16, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bristol-Myers Squibb

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab by itself in treating unresectable melanoma or melanoma that has spread.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Melanoma
Keywords
Cancer, Advanced Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
714 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm A: Relatlimab + Nivolumab
Arm Type
Experimental
Arm Description
Combination
Arm Title
Arm B: Nivolumab
Arm Type
Experimental
Arm Description
Monotherapy
Intervention Type
Biological
Intervention Name(s)
Relatlimab
Intervention Description
Specified dose on specified day
Intervention Type
Biological
Intervention Name(s)
Nivolumab
Intervention Description
Specified dose on specified days
Primary Outcome Measure Information:
Title
Progression Free Survival (PFS)
Description
Progression Free Survival (PFS) is defined as the time between the date of randomization and the date of first documented tumor progression, assessed by a blinded independent central review (BICR) (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. Subjects who die without a reported progression will be considered to have progressed on the date of their death.
Time Frame
From randomization to date of first documented tumor progression or death (up to approximately 33 months)
Secondary Outcome Measure Information:
Title
Overall Survival (OS)
Description
Overall Survival (OS) is defined as the time between the date of randomization and the date of death due to any cause. For subjects that are alive, their survival time will be censored at the date of last contact ("last known alive date").
Time Frame
From randomization to the date of death (up to approximately 3 years)
Title
Overall Response Rate (ORR)
Description
Objective response rate (ORR) is defined as the number of randomized subjects who achieve a best response of complete response (CR) or partial response (PR) based on BICR assessments (using RECIST v1.1 criteria).
Time Frame
From randomization up to approximately 3 years
Other Pre-specified Outcome Measures:
Title
The Number of Participants Experiencing Adverse Events (AEs)
Description
The number of participants experiencing adverse events (AEs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time Frame
From first dose to 30 days after last dose of study therapy (up to approximately 33 months)
Title
The Number of Participants Experiencing Serious Adverse Events (SAEs)
Description
The number of participants experiencing serious adverse events (SAEs). A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.
Time Frame
From first dose to 30 days after last dose of study therapy (up to approximately 33 months)
Title
The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
Description
The number of participants experiencing adverse events (AEs) leading to discontinuation. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time Frame
From first dose to 30 days after last dose of study therapy (up to approximately 33 months)
Title
The Number of Participant Deaths in the Study
Description
The number of participant deaths in the study.
Time Frame
From first dose up to approximately 33 months
Title
The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests
Description
The number of participants with clinical laboratory test abnormalities in specific liver tests based on US conventional units.
Time Frame
From first dose to 30 days after last dose of study therapy (up to approximately 33 months)
Title
The Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests
Description
The number of participants with clinical laboratory test abnormalities in specific thyroid tests based on US conventional units.
Time Frame
From first dose to 30 days after last dose of study therapy (up to approximately 33 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: Participants must have histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the AJCC staging system Participants must not have had prior systemic anticancer therapy for unresectable or metastatic melanoma Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses Exclusion Criteria: Participants must not have active brain metastases or leptomeningeal metastases Participants must not have uveal melanoma Participants must not have an active, known, or suspected autoimmune disease Other protocol defined inclusion/exclusion criteria could apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Local Institution - 0010
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85724-5024
Country
United States
Facility Name
Local Institution - 0020
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
Coastal Integrative Cancer Care
City
San Luis Obispo
State/Province
California
ZIP/Postal Code
93401
Country
United States
Facility Name
Local Institution - 0116
City
Santa Barbara
State/Province
California
ZIP/Postal Code
93105
Country
United States
Facility Name
Local Institution - 0012
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20007
Country
United States
Facility Name
Local Institution - 0013
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Facility Name
Local Institution - 0117
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Local Institution - 0007
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Facility Name
Local Institution - 0038
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Facility Name
Local Institution - 0016
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Local Institution - 0114
City
Fort Wayne
State/Province
Indiana
ZIP/Postal Code
46804
Country
United States
Facility Name
Local Institution - 0077
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21237
Country
United States
Facility Name
Local Institution - 0120
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States
Facility Name
Local Institution - 0014
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Local Institution - 0134
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Local Institution - 0015
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Name
Local Institution - 0009
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55407
Country
United States
Facility Name
Local Institution - 0011
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
Local Institution - 0018
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28204
Country
United States
Facility Name
Local Institution - 0019
City
Allentown
State/Province
Pennsylvania
ZIP/Postal Code
18103
Country
United States
Facility Name
Local Institution - 0076
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Facility Name
Local Institution - 0008
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Local Institution - 0135
City
Buenos Aires
State/Province
Distrito Federal
ZIP/Postal Code
1121
Country
Argentina
Facility Name
Local Institution - 0002
City
Capital Federal
State/Province
Distrito Federal
ZIP/Postal Code
C1280AEB
Country
Argentina
Facility Name
Local Institution - 0004
City
Buenos Aires
ZIP/Postal Code
1199
Country
Argentina
Facility Name
Local Institution - 0005
City
Buenos Aires
ZIP/Postal Code
4102-4200
Country
Argentina
Facility Name
Local Institution - 0003
City
Ciudad Autónoma De Buenos Aires
ZIP/Postal Code
1426
Country
Argentina
Facility Name
Local Institution - 0042
City
North Sydney
State/Province
New South Wales
ZIP/Postal Code
2060
Country
Australia
Facility Name
Local Institution - 0043
City
Waratah
State/Province
New South Wales
ZIP/Postal Code
2298
Country
Australia
Facility Name
Local Institution - 0041
City
Greenslopes
State/Province
Queensland
ZIP/Postal Code
4120
Country
Australia
Facility Name
Local Institution - 0045
City
Southport
State/Province
Queensland
ZIP/Postal Code
4215
Country
Australia
Facility Name
Local Institution - 0133
City
Bedford Park
State/Province
South Australia
ZIP/Postal Code
5042
Country
Australia
Facility Name
Local Institution - 0044
City
Murdoch
State/Province
Western Australia
ZIP/Postal Code
6150
Country
Australia
Facility Name
Local Institution - 0036
City
Graz
ZIP/Postal Code
8036
Country
Austria
Facility Name
Local Institution - 0037
City
Salzburg
ZIP/Postal Code
5020
Country
Austria
Facility Name
Local Institution - 0035
City
Wien
ZIP/Postal Code
1090
Country
Austria
Facility Name
Local Institution - 0047
City
Brussels
ZIP/Postal Code
1090
Country
Belgium
Facility Name
Local Institution - 0049
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Facility Name
Local Institution - 0048
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
Local Institution - 0058
City
Belo Horizonte
State/Province
Minas Gerais
ZIP/Postal Code
30130-090
Country
Brazil
Facility Name
Local Institution - 0057
City
Porto Alegre
State/Province
RIO Grande DO SUL
ZIP/Postal Code
90035-903
Country
Brazil
Facility Name
Local Institution - 0061
City
Porto Alegre
State/Province
RIO Grande DO SUL
ZIP/Postal Code
91350-200
Country
Brazil
Facility Name
Local Institution - 0073
City
Santa Cruz do Sul
State/Province
RIO Grande DO SUL
ZIP/Postal Code
96810-110
Country
Brazil
Facility Name
Local Institution - 0063
City
São Paulo
State/Province
SAO Paulo
ZIP/Postal Code
05651-901
Country
Brazil
Facility Name
Local Institution - 0059
City
Rio De Janiro
ZIP/Postal Code
20220-410
Country
Brazil
Facility Name
Local Institution - 0060
City
Sao Paulo
ZIP/Postal Code
01246-000
Country
Brazil
Facility Name
Local Institution - 0062
City
Sao Paulo
ZIP/Postal Code
01509-010
Country
Brazil
Facility Name
Local Institution - 0124
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 2Y9
Country
Canada
Facility Name
Local Institution - 0068
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 8L6
Country
Canada
Facility Name
Local Institution - 0128
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Facility Name
Local Institution - 0123
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1E2
Country
Canada
Facility Name
Local Institution - 0075
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4A 3J1
Country
Canada
Facility Name
Local Institution - 0001
City
Santiago
State/Province
Metropolitana
Country
Chile
Facility Name
Local Institution - 0096
City
Medellín
State/Province
Antioquia
ZIP/Postal Code
050030
Country
Colombia
Facility Name
Local Institution - 0095
City
Bogota
ZIP/Postal Code
110321
Country
Colombia
Facility Name
Local Institution - 0105
City
Aarhus N
ZIP/Postal Code
8200
Country
Denmark
Facility Name
Local Institution - 0103
City
Herlev
ZIP/Postal Code
2730
Country
Denmark
Facility Name
Local Institution - 0104
City
Odense
ZIP/Postal Code
5000
Country
Denmark
Facility Name
Local Institution - 0100
City
Helsinki
State/Province
Uusimaa
ZIP/Postal Code
00290
Country
Finland
Facility Name
Local Institution - 0102
City
Oulu
ZIP/Postal Code
90220
Country
Finland
Facility Name
Local Institution - 0119
City
Tampere
ZIP/Postal Code
33521
Country
Finland
Facility Name
Local Institution - 0101
City
Turku
ZIP/Postal Code
20520
Country
Finland
Facility Name
Local Institution - 0084
City
Rennes
State/Province
Ille-et-Vilaine
ZIP/Postal Code
35042
Country
France
Facility Name
Local Institution - 0079
City
Amiens
State/Province
Somme
ZIP/Postal Code
80000
Country
France
Facility Name
Local Institution - 0080
City
Bordeaux Cedex
ZIP/Postal Code
33075
Country
France
Facility Name
Local Institution - 0085
City
Lille
ZIP/Postal Code
59000
Country
France
Facility Name
Local Institution - 0081
City
Marseille
ZIP/Postal Code
13011
Country
France
Facility Name
Local Institution - 0083
City
Paris
ZIP/Postal Code
75010
Country
France
Facility Name
Local Institution - 0078
City
Pierre-Benite
ZIP/Postal Code
69310
Country
France
Facility Name
Local Institution - 0082
City
Poitiers
ZIP/Postal Code
86000
Country
France
Facility Name
Local Institution - 0131
City
Tübingen
State/Province
Baden-Württemberg
ZIP/Postal Code
72076
Country
Germany
Facility Name
Local Institution - 0071
City
Quedlinburg
State/Province
Sachsen-Anhalt
ZIP/Postal Code
06484
Country
Germany
Facility Name
Local Institution - 0032
City
Buxtehude
ZIP/Postal Code
21614
Country
Germany
Facility Name
Local Institution - 0030
City
Erfurt
ZIP/Postal Code
99089
Country
Germany
Facility Name
Local Institution - 0027
City
Essen
ZIP/Postal Code
45147
Country
Germany
Facility Name
Local Institution - 0033
City
Hannover
ZIP/Postal Code
30625
Country
Germany
Facility Name
Local Institution - 0132
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
Facility Name
Local Institution - 0074
City
Homburg / Saar
ZIP/Postal Code
66421
Country
Germany
Facility Name
Local Institution - 0029
City
Köln
ZIP/Postal Code
50937
Country
Germany
Facility Name
Local Institution - 0028
City
Lubeck
ZIP/Postal Code
23538
Country
Germany
Facility Name
Local Institution - 0072
City
Mannheim
ZIP/Postal Code
68167
Country
Germany
Facility Name
Local Institution - 0034
City
Muenchen
ZIP/Postal Code
81675
Country
Germany
Facility Name
Local Institution - 0031
City
Wuerzburg
ZIP/Postal Code
97080
Country
Germany
Facility Name
Local Institution - 0064
City
Athens
ZIP/Postal Code
11526
Country
Greece
Facility Name
Local Institution - 0065
City
Thessaloniki
ZIP/Postal Code
54622
Country
Greece
Facility Name
Local Institution - 0086
City
Haifa
ZIP/Postal Code
3109601
Country
Israel
Facility Name
Local Institution - 0088
City
Jerusalem
ZIP/Postal Code
91120
Country
Israel
Facility Name
Local Institution - 0087
City
Ramat-gan
ZIP/Postal Code
52621
Country
Israel
Facility Name
Local Institution - 0111
City
Torino
State/Province
Piemonte
ZIP/Postal Code
10126
Country
Italy
Facility Name
ASST Papa Giovanni XXIII - Azienda Ospedaliera Papa Giovanni XXIII
City
Bergamo
ZIP/Postal Code
24127
Country
Italy
Facility Name
Local Institution - 0108
City
Milano
ZIP/Postal Code
20133
Country
Italy
Facility Name
Istituto Nazionale Tumori Fondazione Pascale
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Facility Name
Istituto Oncologico Veneto IOV
City
Padova
ZIP/Postal Code
35128
Country
Italy
Facility Name
AOUS - Policlinico S.Maria Alle Scotte
City
Siena
ZIP/Postal Code
53100
Country
Italy
Facility Name
Local Institution - 0094
City
Zapopan
State/Province
Jalisco
ZIP/Postal Code
45070
Country
Mexico
Facility Name
Local Institution - 0091
City
Monterrey
State/Province
Nuevo LEON
ZIP/Postal Code
64060
Country
Mexico
Facility Name
Local Institution - 0093
City
Cancún
State/Province
Quintana Roo
ZIP/Postal Code
77500
Country
Mexico
Facility Name
Local Institution - 0092
City
Merida
State/Province
Yucatan
ZIP/Postal Code
97134
Country
Mexico
Facility Name
Local Institution - 0129
City
Veracruz
ZIP/Postal Code
91900
Country
Mexico
Facility Name
Local Institution - 0090
City
Dunedin
ZIP/Postal Code
9012
Country
New Zealand
Facility Name
Local Institution - 0125
City
Hamilton
ZIP/Postal Code
3240
Country
New Zealand
Facility Name
Local Institution - 0089
City
Tauranga
ZIP/Postal Code
3112
Country
New Zealand
Facility Name
Local Institution - 0121
City
Oslo
ZIP/Postal Code
0310
Country
Norway
Facility Name
Local Institution - 0040
City
Poznan
State/Province
Wielkopolskie
ZIP/Postal Code
60-780
Country
Poland
Facility Name
Local Institution - 0039
City
Warszawa
ZIP/Postal Code
02-781
Country
Poland
Facility Name
Local Institution - 0070
City
Cluj-Napoca
State/Province
Cluj
ZIP/Postal Code
400015
Country
Romania
Facility Name
Local Institution - 0066
City
Bucharest
ZIP/Postal Code
 022328
Country
Romania
Facility Name
Local Institution - 0067
City
Craiova
ZIP/Postal Code
200542
Country
Romania
Facility Name
Local Institution - 0069
City
Iasi
ZIP/Postal Code
700483
Country
Romania
Facility Name
Local Institution - 0113
City
Krasnodar
ZIP/Postal Code
350040
Country
Russian Federation
Facility Name
Local Institution - 0127
City
Krasnoyarsk
ZIP/Postal Code
660133
Country
Russian Federation
Facility Name
Local Institution - 0112
City
Moscow
ZIP/Postal Code
115478
Country
Russian Federation
Facility Name
Local Institution - 0023
City
A Coruña
ZIP/Postal Code
15006
Country
Spain
Facility Name
Local Institution - 0024
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Local Institution - 0025
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Local Institution - 0026
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Facility Name
Local Institution - 0021
City
San Sabastian Gipuzkoa
ZIP/Postal Code
20014
Country
Spain
Facility Name
Local Institution - 0022
City
Sevilla
ZIP/Postal Code
41009
Country
Spain
Facility Name
Local Institution - 0098
City
Goteborg
ZIP/Postal Code
413 45
Country
Sweden
Facility Name
Local Institution - 0099
City
Lund
ZIP/Postal Code
221 85
Country
Sweden
Facility Name
Local Institution - 0118
City
Solna
ZIP/Postal Code
171 64
Country
Sweden
Facility Name
Local Institution - 0122
City
Uppsala
ZIP/Postal Code
751 85
Country
Sweden
Facility Name
Local Institution - 0052
City
Bristol
State/Province
Avon
ZIP/Postal Code
BS2 8ED
Country
United Kingdom
Facility Name
Local Institution - 0054
City
Glasgow
State/Province
Dumfries & Galloway
ZIP/Postal Code
G12 0YN
Country
United Kingdom
Facility Name
Local Institution - 0056
City
Swansea
State/Province
Glamorgan
ZIP/Postal Code
SA2 8QA
Country
United Kingdom
Facility Name
Local Institution - 0051
City
London
State/Province
Greater London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Facility Name
Local Institution - 0126
City
Inverness
State/Province
Inverness-shire
ZIP/Postal Code
IV2 3UJ
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
34986285
Citation
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutierrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970.
Results Reference
derived
Links:
URL
https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Description
BMS Clinical Trial Information
URL
http://www.BMSStudyConnect.com
Description
BMS Clinical Trial Patient Recruiting

Learn more about this trial

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

We'll reach out to this number within 24 hrs